(Q35580811)

9 August 2017

1 reference

title

Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies (English)

1 reference

9 August 2017

Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies (English)

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

31 March 2024

author name string

Gavin Giovannoni

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

9 August 2017

11 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14610104

full work available at URL

31 March 2024

https://www.neurology.org/doi/pdfdirect/10.1212/01.WNL.0000092379.75791.5D

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

31 March 2024

1 reference

9 August 2017

volume

61

1 reference

9 August 2017

issue

9 Suppl 5

1 reference

9 August 2017

page(s)

S13-7

1 reference

Bioequivalence and the immunogenicity of biopharmaceuticals

9 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

31 March 2024

3

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

31 March 2024

6

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

31 March 2024

7

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Thrombocytopenia caused by the development of antibodies to thrombopoietin

31 March 2024

8

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor

31 March 2024

9

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β

31 March 2024

10

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast forma

31 March 2024

11

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

31 March 2024

12

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

31 March 2024

13

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

31 March 2024

15

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

31 March 2024

16

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

31 March 2024

17

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Pure red-cell aplasia due to anti-erythropoietin antibodies

31 March 2024

18

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

31 March 2024

20

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view

31 March 2024

21

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

31 March 2024

22

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

31 March 2024

23

85

15

2000

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

31 March 2024

24

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

The epidemiology of inhibitors in haemophilia A: a systematic review

31 March 2024

25

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies

31 March 2024

26

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I

31 March 2024

28

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

International journal of MS care

31 March 2024

29

2

1

1999

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

European Cytokine Network

31 March 2024

30

12

56

2001

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000092379.75791.5D

31 March 2024

Identifiers

1 reference

9 August 2017

1 reference